| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = $962,488 ) |
| | 2021 | 2021 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R44HD084033 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings | 000 | 6 | NIH | 4/16/2021 | $962,488 |
|
| Issue Date FY: 2020 ( Subtotal = $964,308 ) |
| | 2020 | 2020 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R44HD084033 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings | 002 | 5 | NIH | 4/10/2020 | $964,308 |
| | 2020 | 2019 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R01AI117059 | A fully integrated CentriFluidic system for direct bloodstream infection PID/AST | 000 | 5 | NIH | 9/22/2020 | $0 |
| | 2020 | 2018 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | SB1AI088756 | Near patient molecular diagnostics test for infections | 000 | 8 | NIH | 12/12/2019 | $0 |
| | 2020 | 2017 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R44HD084033 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings | 001 | 3 | NIH | 3/26/2020 | $0 |
| | 2020 | 2015 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R44HD084033 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings | 000 | 1 | NIH | 3/26/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,655,952 ) |
| | 2019 | 2019 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R01AI117059 | A fully integrated CentriFluidic system for direct bloodstream infection PID/AST | 000 | 5 | NIH | 2/12/2019 | $689,192 |
| | 2019 | 2019 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R44HD084033 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings | 001 | 4 | NIH | 5/11/2019 | $966,760 |
| | 2019 | 2017 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R44HD084033 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings | 000 | 3 | NIH | 5/9/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,692,753 ) |
| | 2018 | 2018 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R01AI117059 | A fully integrated CentriFluidic system for direct bloodstream infection PID/AST | 000 | 4 | NIH | 2/1/2018 | $692,753 |
| | 2018 | 2018 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | SB1AI088756 | Near patient molecular diagnostics test for infections | 000 | 8 | NIH | 7/13/2018 | $1,000,000 |
|
| Issue Date FY: 2017 ( Subtotal = $2,383,204 ) |
| | 2017 | 2017 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | SB1AI088756 | Near patient molecular diagnostics test for infections | 001 | 7 | NIH | 8/25/2017 | -$1,000,000 |
| | 2017 | 2017 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R01AI117059 | A fully integrated CentriFluidic system for direct bloodstream infection PID/AST | 002 | 3 | NIH | 3/2/2017 | $704,237 |
| | 2017 | 2017 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | SB1AI088756 | Near patient molecular diagnostics test for infections | 001 | 7 | NIH | 8/25/2017 | $1,000,000 |
| | 2017 | 2017 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | SB1AI088756 | Near patient molecular diagnostics test for infections | 000 | 7 | NIH | 8/8/2017 | $1,000,000 |
| | 2017 | 2017 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R44HD084033 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings | 000 | 3 | NIH | 6/22/2017 | $747,857 |
| | 2017 | 2016 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R01AI117059 | A fully integrated CentriFluidic system for direct bloodstream infection PID/AST | 001 | 2 | NIH | 3/1/2017 | -$30,569 |
| | 2017 | 2015 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R01AI117059 | A fully integrated CentriFluidic system for direct bloodstream infection PID/AST | 000 | 1 | NIH | 3/1/2017 | -$38,321 |
| | 2017 | 2015 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R43CA199211 | Promote HPV screening rate with a non-invasive HPV POC cartridge | 000 | 1 | NIH | 11/28/2016 | $0 |
| | 2017 | 2014 | GENEFLUIDICS, INC. | 845 MERIDIAN STREET | IRWINDALE | CA | 91010-3588 | | USA | R44AI088756 | An Integrated Diagnostic System for Rapid Antimicrobial Susceptibility Testing | 000 | 5 | NIH | 8/4/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $2,470,625 ) |
| | 2016 | 2016 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | SB1AI088756 | Near patient molecular diagnostics test for infections | 000 | 6 | NIH | 7/28/2016 | $989,569 |
| | 2016 | 2016 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R44HD084033 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings | 000 | 2 | NIH | 7/1/2016 | $747,722 |
| | 2016 | 2016 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R01AI117059 | A fully integrated CentriFluidic system for direct bloodstream infection PID/AST | 000 | 2 | NIH | 3/10/2016 | $733,334 |
| | 2016 | 2015 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R43CA199211 | Promote HPV screening rate with a non-invasive HPV POC cartridge | 000 | 1 | NIH | 2/26/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $1,317,669 ) |
| | 2015 | 2015 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R01AI117059 | A fully integrated CentriFluidic system for direct bloodstream infection PID/AST | 000 | 1 | NIH | 2/17/2015 | $869,572 |
| | 2015 | 2015 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R44HD084033 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings | 000 | 1 | NIH | 4/24/2015 | $224,468 |
| | 2015 | 2015 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R43CA199211 | Promote HPV screening rate with a non-invasive HPV POC cartridge | 000 | 1 | NIH | 7/6/2015 | $223,629 |
|
| Issue Date FY: 2014 ( Subtotal = $987,161 ) |
| | 2014 | 2014 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R44AI088756 | An Integrated Diagnostic System for Rapid Antimicrobial Susceptibility Testing | 000 | 5 | NIH | 7/10/2014 | $987,161 |
|
| Issue Date FY: 2013 ( Subtotal = $989,486 ) |
| | 2013 | 2013 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R44AI088756 | An Integrated Diagnostic System for Rapid Antimicrobial Susceptibility Testing | 000 | 4 | NIH | 4/22/2013 | $989,486 |
|
| Issue Date FY: 2012 ( Subtotal = $997,129 ) |
| | 2012 | 2012 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R44AI088756 | An Integrated Diagnostic System for Rapid Antimicrobial Susceptibility Testing | 000 | 3 | NIH | 5/31/2012 | $997,129 |
|
| Issue Date FY: 2011 ( Subtotal = $574,203 ) |
| | 2011 | 2011 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R43HD065303 | RAPID ANTIBIOTIC SUSCEPTIBILITY TESTING FOR NEONATAL INTENSIVE UNITS | 001 | 2 | NIH | 6/28/2011 | $2,159 |
| | 2011 | 2011 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R43HD065303 | RAPID ANTIBIOTIC SUSCEPTIBILITY TESTING FOR NEONATAL INTENSIVE UNITS | 000 | 2 | NIH | 6/7/2011 | $213,717 |
| | 2011 | 2011 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R43AI088756 | RAPID ANTIMICROBIAL SUSCEPTIBILITY TEST CARTRIDGE FOR RESOURCE-LIMITED SETTINGS | 000 | 2 | NIH | 2/14/2011 | $358,327 |
|
| Issue Date FY: 2010 ( Subtotal = $657,799 ) |
| | 2010 | 2010 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R43HD065303 | RAPID ANTIBIOTIC SUSCEPTIBILITY TESTING FOR NEONATAL INTENSIVE UNITS | 000 | 1 | NIH | 4/15/2010 | $218,454 |
| | 2010 | 2010 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R43AI091213 | RAPID PROTOTYPING METHOD AND DESIGN LIBRARY FOR UNIVERSAL POC APPLICATION | 000 | 1 | NIH | 7/19/2010 | $97,205 |
| | 2010 | 2010 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R43AI088756 | RAPID ANTIMICROBIAL SUSCEPTIBILITY TEST CARTRIDGE FOR RESOURCE-LIMITED SETTINGS | 000 | 1 | NIH | 3/9/2010 | $342,140 |
|
| Issue Date FY: 2002 ( Subtotal = $128,762 ) |
| | 2002 | 2002 | GENEFLUIDICS INC | 2540 CORPORATE PLACE | MONTEREY PARK | CA | 91754 | LOS ANGELES | USA | R43CA096065 | RAPID MOLECULAR DETECTION OF PML/RARALPHA | 000 | 1 | NIH | 4/12/2002 | $128,762 |
|
|
